Genistein inhibits prostate cancer cell growth by targeting miR-34a and oncogenic HOTAIR

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Genistein exhibits antitumor properties against various cancers, including prostate cancer (PCa).
• Genistein's mechanism involves regulating cell signaling pathways and microRNAs (miRNAs).
• Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in cellular processes, yet their interaction with genistein and miRNAs in PCa remains unexplored.

Purpose of the Study:

• To investigate the regulatory effects of genistein on specific miRNAs and lncRNAs in PCa.
• To elucidate the functional roles of these regulated molecules in PCa progression.
• To explore the interplay between genistein, miRNAs, and lncRNAs in the context of PCa.

Main Methods:

• Gene expression profiling using microarray to identify differentially expressed genes in genistein-treated vs. control PCa cells.
• In vitro functional assays (proliferation, migration, invasion, apoptosis, cell cycle) in PCa cell lines (PC3, DU145).
• In vivo growth assays in nude mouse models and luciferase reporter assays to confirm direct targeting of HOTAIR by miR-34a.

Main Results:

• Genistein significantly altered lncRNA expression, notably up-regulating HOTAIR in castration-resistant PCa cells.
• Knockdown of HOTAIR suppressed PCa cell proliferation, migration, and invasion, while inducing apoptosis and cell cycle arrest.
• Genistein treatment increased miR-34a expression, and miR-34a was found to directly target HOTAIR.

Conclusions:

• Genistein inhibits PCa cell growth by down-regulating the oncogenic lncRNA HOTAIR.
• The tumor suppressor miR-34a directly targets and regulates HOTAIR expression.
• These findings provide novel insights into the molecular mechanisms by which genistein exerts its antitumor effects in PCa via HOTAIR and miR-34a regulation.